Biogen Inc (BUE:BIIB)
ARS 18636 201.5 (1.09%) Market Cap: 28.98 Til Enterprise Value: 34.17 Til PE Ratio: 28.13 PB Ratio: 2.14 GF Score: 49/100

Biogen Inc Aducanumab Webinar Update Transcript

Feb 23, 2021 / 07:00PM GMT
Release Date Price: ARS2990 (+2.15%)
John Dwyer

Allow me to welcome, everyone, to this very important presentation by our colleagues from Biogen. This is John Dwyer, President of the Global Alzheimer's Platform Foundation. This was initially intended as a discussion of the science and clinical aspects of Biogen's drug aducanumab, and we broadened it to the public, which I think is terrific. So let me just say a word about who GAP is for those of you on this call that don't know us.

The Global Alzheimer's Platform Foundation's mission is to reduce the duration and cost and improve the quality of Alzheimer's disease clinical therapeutic studies. Not a trivial mission, to say the least. Over the last 6 years, we have combined with our network of over 80 truly leading clinical trial sites in North America to try and accelerate and improve clinical trials for a variety of different Alzheimer's therapies. We're proud to say one of those was Biogen's. And it is with that background that we have in our audience, all of our sites, I hope, their PIs and staff who have worked so hard to bring aducanumab to the place where it is and other very

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot